In advanced bladder cancer, Bellmunt et al. were the first to report that patients with a high mRNA level of ERCC1 had poorer prognosis for cisplatin-based chemotherapy than did patients with a low mRNA level of ERCC1 [17]. Here, ERCC1 is linked to urinary bladder cancer.